Interestingly, the incidence of drug-induced pneumonitis at the higher 6.4 mg/kg dose of T-DXd was reported in 10% (n = 12: three grade 1, six grade 2, two grade 3, one grade 4, and no grade 5 events) of HER2-positive gastric cancer patients in the DESTINY-Gastric01 trial [121], while 28% (n = 14: four grade 1, nine grade 2, one grade 5) of HER2-mutant metastatic NSCLC patients had adjudicated drug-related ILD in the phase 2 DESTINY-Lung02 trial [41]. Here, ERBB2 is linked to gastric cancer.